Season 2 - Ep.15: Omega-3 fatty acids - Lead induced tricuspid regurgitation

May 9, 2024

Guest

Deepak Bhatt

Guest

Martin Andreas

Guest

Carlos Aguiar

Cardiology experts Carlos Aguiar and Deepak Bhatt discuss omega-3 fatty acids benefits and lead-induced tricuspid regurgitation. They explore TAVI outcomes, heart failure, genetic predispositions, and the impact of EPA on cardiovascular health. Martin Andreas provides insights on tricuspid regurgitation in patients with implanted leads. Mythbusters segment examines the effects of pomegranates on heart health.

Ask episode

Chapters

Transcript

Episode notes

Introduction

00:00 • 2min

Insights on Heart Failure, Ablation, Genotype Carriers, and Lipid Therapy in the Elderly

01:57 • 5min

Cardiovascular Benefits of EPA

06:29 • 6min

Tricuspid Regurgitation in Patients with Implanted Leads

12:38 • 5min

Exploring the Effects of Pomegranates on Cardiovascular Health

17:28 • 4min

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly.

This episode covers:

Cardiology This Week: A concise summary of recent studies
All you need to know about omega-3 fatty acids
Lead induced tricuspid regurgitation
MythBusters: Pomegranates are heart-healthy

Host: Rick Grobbee

Guests: Carlos Aguiar, Martin Andreas, Deepak Bhatt

Want to watch that episode? Go to: https://esc365.escardio.org/event/1150

Disclaimer

This programme is intended for health care professionals only and is to be used for educational purposes.

The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.

Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

Declarations of interests

Stephan Achenbach, Rick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report.

Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede.

Martin Andreas has declared to have potential conflicts of interest to report: proctor/speaker/consultant (Edwards, Abbott, Medtronic, Boston, Braun, Zoll) and institutional Research Grants (Edwards, Abbott, Medtronic, LSI).

Deepak Bhatt has declared to have potential conflicts of interest to report: research funding from Amarin paid to Brigham and Women’s Hospital and the Icahn School of Medicine at Mount Sinai for my role as Principal Investigator of REDUCE-IT.

Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Novo Nordisk, Sanofi. Terumo, Medtronic.

Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.